Results of clinical trial on BioCell Collagen for Joint Health Published in the Journal of Agricultural and Food Chemistry
Human clinical study confirms earlier studies demonstrating the benefits of BioCell Collagen’s ability to improve joint discomfort and overall quality of life.
April 18, 2012, Newport Beach, CA- In results of a multi-center, double-blind, placebo-controlled human clinical study published by the prestigious Journal of Agriculture and Food Chemistry; researchers found that people experienced significant improvement in their joint discomfort levels, and ability to participate in everyday activities, after taking BioCell Collagen.
BioCell Collagen contains highly bioavailable forms of the major constituents of human joints: collagen type II, hyaluronic acid and chondroitin sulfate. There are more than 14 different types of collagen found in the body. Collagen type II is the main structural building block of soft connective tissue and joint cartilage. Previous studies have demonstrated that BioCell Collagen is effectively absorbed into the bloodstream, and indicate that hydrolyzed collagen-derived peptides are deposited into the joint cartilage to protect and to stimulate the chondrocytes to produce novel collagen type II and other molecules essential for the cartilage structure.
“This ingredient has a lower molecular weight than other forms of joint supplements, which appears to be an important reason for its effectiveness,” comments Jerome Stenehjem, MD, School of Medicine, University of California at San Diego, a principle study investigator. “It is possible that nutrients such as those found in this patented supplement may improve the quality of the joint fluid, thereby supporting better joint health.”
Clinical trial details
This recent study involved 80 subjects. They received either one gram twice daily of BioCell Collagen or a placebo for 70 days. The treatment group experienced a significant improvement. All primary endpoint were met for statistical significance. The percentage of the subjects who experienced at least 30% improvement was 40% in the BioCell Collagen group and only 3% in the placebo. BioCell Collagen was well tolerated by the subjects in the clinical trial.
“This was the largest randomized controlled human study to date of BioCell Collagen, and it confirms previous studies that demonstrated similar effectiveness and safety,” stated Stenehjem.
Added study investigator Alexander G. Schauss, PhD, FACN, Senior Director of AIBMR Life Sciences, “This was a well-designed study published by one of the most recognized scientific journals in the world. We are pleased that results build on the substantial body of evidence indicating BioCell Collagen’s potential to make a difference in people’s lives.”
The abstract to the clinical trial can be found on the journal website or via the following link:
http://www.ncbi.nlm.nih.gov/pubmed/22486722
BioCell Collagen is readily available as a stand-alone supplement as well as an ingredient in other nutritional supplements. For additional information, visit www.BioCellCollagen.com.
About BioCell Technology:
Founded in 1997, BioCell Technology, LLC is the exclusive supplier of BioCell Collagen. BioCell Technology, LLC owns the exclusive rights to market BioCell Collagen under the United States Patents. BioCell Collagen is a branded registered logo that is available for display on its client’s labels to market under their own brand name or formulas. For more information on BioCell Collagen, please contact BioCell Technology, LLC at (714) 632-1231, or visit them at https://www.biocelltechnology.com.
